The Contract Pharmaceutical Research Services industry provides a breadth of research and development (R&D) services to manufacturers in the pharmaceutical industries. In the past five years, brand-name drug producers have faced increasing threats from generic brands due to patent expirations. Additionally, increased regulation and emergent health economics and outcomes research have pressured pharmaceutical companies to control costs and increase research efficiency. The industry is poised for continued growth in the five years to 2021. During this time, healthcare reform will expand the pharmaceutical industry's total market and increased approvals for generic brands will continue to pressure branded drug manufacturers. As a result, cost control and research productivity will continue to be essential objectives of drug production, increasing demand for industry services.
The industry provides a range of research and development services to pharmaceutical manufacturers, including laboratory testing, preclinical and clinical trials, commercialization and post-market surveillance.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.